Measuring vaccine effectiveness against persistent HPV infections: a comparison of different statistical approaches

R. Donken*, J. Hoes, M. J. Knol, G. S. Ogilvie, S. Dobson, A. J. King, J. Singer, P. J. Woestenberg, J. A. Bogaards, C. J. L. M. Meijer, H. E. de Melker

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

BackgroundPersistent high-risk human papillomavirus (HPV) infection is endorsed by the World Health Organization as an intermediate endpoint for evaluating HPV vaccine effectiveness/efficacy. There are different approaches to estimate the vaccine effectiveness/efficacy against persistent HPV infections.MethodsWe performed a systematic literature search in Pubmed to identify statistical approaches that have been used to estimate the vaccine effectiveness/efficacy against persistent HPV infections. We applied these methods to data of a longitudinal observational study to assess their performance and compare the obtained vaccine effectiveness (VE) estimates.ResultsOur literature search identified four approaches: the conditional exact test for comparing two independent Poisson rates using a binomial distribution, Generalized Estimating Equations for Poisson regression, Prentice Williams and Peterson total time (PWP-TT) and Cox proportional hazards regression. These approaches differ regarding underlying assumptions and provide different effect measures. However, they provided similar effectiveness estimates against HPV16/18 and HPV31/33/45 persistent infections in a cohort of young women eligible for routine HPV vaccination (range VE 93.7-95.1% and 60.4-67.7%, respectively) and seemed robust to violations of underlying assumptions.ConclusionsAs the rate of subsequent infections increased in our observational cohort, we recommend PWP-TT as the optimal approach to estimate the vaccine effectiveness against persistent HPV infections in young women. Confirmation of our findings should be undertaken by applying these methods after longer follow-up in our study, as well as in different populations.

Original languageEnglish
Article number482
Number of pages11
JournalBMC Infectious Diseases
Volume20
Issue number1
DOIs
Publication statusPublished - 8 Jul 2020

Keywords

  • Human papillomavirus
  • HPV
  • Persistent infection
  • HPV vaccination
  • Follow-up
  • HPV-16/18 AS04-ADJUVANTED VACCINE
  • HUMAN-PAPILLOMAVIRUS TYPE-16
  • CROSS-PROTECTIVE EFFICACY
  • PATRICIA RANDOMIZED-TRIAL
  • SUSTAINED EFFICACY
  • DOUBLE-BLIND
  • PARTICLE VACCINE
  • YOUNG-WOMEN
  • FOLLOW-UP
  • CERVICAL COINFECTION

Cite this